SLC16A1 and breast cancer: However, the strategy fails to kill triple negative MDA-MB-231 breast cancer cells, where a sufficiently low pHi was unattainable (Supplementary Figure 15), presumably due to the elevated expression of the MCT4 transporter that is resistant to the effects of the selective MCT1/2 inhibitor35,36.